Akiram Therapeutics
Recent Finacing
Equity
Recent Raise
$6.5M
Akiram Therapeutics develops a targeted radioimmunotherapy combining a proprietary antibody with lutetium‑177, advancing a lead candidate for anaplastic thyroid and other thyroid/head‑and‑neck cancers toward clinical trials.
Highlights
Focus Areas
Biotechnology
Life Science
Precision Medicine
Recent Investors
Financials
$6.5M
Total Raised
1
Funding round
2
Investors